C3 Industries has opened a new medical cannabis dispensary in London, Kentucky. This marks the Company’s entry into the state and expands access to safe medical cannabis for registered patients in Laurel County and the surrounding southeastern Kentucky region.

Kentucky launched its medical cannabis program on January 1, 2025, and many residents are still navigating the certification process for the first time. High Profile London supports new and innovative cardholders with an expert team and a welcoming retail experience.

Located at 140 Faith Assembly Church Road, London, KY, High Profile London is a medical-only dispensary serving registered Kentucky patients 18 years of age and older with a qualifying condition. The store offers a curated selection of flowers, edibles, vapes, concentrates and accessories, along with in-store shopping and online ordering for added convenience.

“As our retail network expands into Kentucky, we are focused on opening doors to patients in markets where access is still new, and simplifying the patient process that can feel complicated,” said Ankur Rungta, CEO and co-founder of C3 Industries. “London is exactly the kind of community where High Profile can make a difference. Our team is working to remove the barriers that prevent patients from getting the care they need.”

© C3 Industries

The Kentucky Cannabis Industry Association (KCIA) is hosting weekly Patient Drives at High Profile London every Thursday in May from 12pm to 4pm to help qualified patients navigate the Kentucky cannabis certification process. At this event, patients can meet with independent practitioners to complete their certification and necessary paperwork in one appointment for a $25 fee. A separate state registration fee of $25 is also required. New patients and renewals are welcome. Tours will be adjusted as the schedule allows.

Easily accessible from I-75 and conveniently located in Laurel County, the dispensary provides convenient access for patients in southeastern Kentucky. Store hours are Tuesday through Thursday, 10:00 a.m. to 6:00 p.m., and Friday through Saturday, 11:00 a.m. to 8:00 p.m., soon to be extended hours. Weekly patient trips, rotating promotions and daily deals are available on a convenient range of brands and products. Terms and conditions apply.

“At High Profile, the customer sits at the center of everything we do. Then we build the experience around them, with the right information, the right selection and the right price for every visit,” said Chris Melillo, Chief Retail Officer, C3 Industries. “Whether a patient is getting their first medical card or has been a cannabis patient for years, our job is to meet them where they are in their journey. That’s what we’re bringing to London, and we can’t wait to introduce ourselves to the community.”

A bipartisan coalition of 32 members of Congress is urging federal health officials to speed up ongoing reviews of psychedelic therapies.

“For many people, current treatment options are insufficient, deepening an already urgent public health crisis,” wrote lawmakers, Reps. Jack Bergman (R-MI) and Lou Correa (D-CA), chair of the Congressional Psychedelics Advancing Therapies Caucus, in a letter to the head of the Food and Drug Administration (FDA). “As members of the House of Representatives, we have heard from countless veterans, clinicians and families seeking evidence-based alternatives.”

The letter to FDA Commissioner Marty Makary says lawmakers are “encouraged” by his recent statement that psychedelic treatments are “a top priority for this FDA and this administration.”

The FDA and the Department of Health and Human Services (HHS) announced steps last month that they say will help “expediting” therapeutic access to psychedelics for patients suffering from serious mental health conditions.

That movement a President Donald Trump signed an executive order on psychedelics.

The lawmakers’ new letter said they want the FDA to conduct “expeditious and rapid review of promising treatments,” especially those that address urgent unmet needs in PTSD, traumatic brain injury and other neuropsychiatric conditions, but “understand and respect the agency’s role in ensuring that new treatments meet rigorous safety and efficacy standards.”

They said recent developments, including the public release of documents related to the denial of MDMA-assisted therapy approval during the Biden administration, “highlight the complexity of evaluating innovative treatment modalities and underscore the need for clear and consistent expectations for this emerging field.”

Members of Parliament have several questions for Makary to answer:

• Specific Protocol Assessment (SPA): How does FDA communicate and apply other data concerns beyond clearly defined primary endpoints and control conditions when pivotal trials are conducted in a SPA? Are improvements being made to anticipate regulatory expectations for therapies in developing areas?
• Methodological standards and interagency coordination: What steps FDA is taking to clarify methodological expectations for entactogen- and psychedelic-assisted clinical trials—including strategies to mitigate functional illusion and expectancy effects—and how the agency is coordinating with federal partners, such as the US Department of Veterans Affairs, to meet urgent research needs in populations such as the US Department of Veterans Affairs. Veterans with PTSD.
• Review integrity and subject matter expertise: How does the FDA ensure that reviews of entactogenic and psychedelic-assisted therapies are conducted by qualified experts with relevant experience? What steps are there in the evaluation process to ensure consistency, objectivity and independence?
• Timeline for final guidance: What is the timeline for finalizing the FDA’s June 2023 guidance on accelerated clinical trials of new therapeutics, including entactogen- and psychedelic-assisted therapies?

They are also encouraging clarification in any new FDA guidance on:

• Strategies to mitigate functional desistance and expectancy bias;
• Adverse event monitoring and security reporting rules;
• Provider training, licensing and participant protections;
• The evolving role of psychotherapy alongside pharmacological intervention;
• Generalizability of findings to different patient populations; and
• Consistency of regulatory expectations for entactogenic and psychedelic drug development programs.

“We remain committed to ensuring that veterans and others with treatment-resistant mental health conditions have access to safe, evidence-based care,” the lawmakers said. he wrote. “We respectfully urge the FDA to continue its evaluation of entactogen- and psychedelic-assisted therapies with transparency, urgency, and scientific rigor while the agency fulfills its statutory responsibilities.”

In addition to Bergman and Correa, other lawmakers who signed the letter include: Dan Crenshaw (R-TX), Morgan Luttrell (R-TX), Pete Sessions (R-TX), Alexandria Ocasio-Cortez (D-NY), Nancy Mace (R-SC), Mark Pocan (D-WI), Mariannette Miller-Meeks (R-WI Orden) and Derrick Van Orden (R-WI).

Robert F. Kennedy Jr. HHS Secretary said recently The Trump administration is “very eager” to create a pathway to access psychedelic therapy and that senior officials at federal agencies want to “get it out to the public as soon as possible.”

In an interview with the Joe Rogan Experience in February, Kennedy said he was confident “we’re going to get it,” with plans to develop and finalize rules that would allow patients with conditions like post-traumatic stress disorder (PTSD) and depression to access psychedelic substances like psilocybin and MDMA in a “very controlled environment.”

“Everyone at my agency … is very eager to get a rule that will allow these types of studies and allow access to these products in therapeutic settings, particularly for military personnel who have sustained these injuries,” the HHS secretary said. “We are working on that process now. We are all working and trying to make it happen.”

“I think we’ll make it,” he said.

Last June, Kennedy said that his agency “Fully committed” to expanding research into the benefits of psychedelic therapy. and, along with the head of the FDA, aims to give military veterans legal access to these substances “within 12 months.”

Veterans Affairs Secretary Doug Collins also announced in April that he had an “eye-opening” conversation with Kennedy. On the therapeutic potential of psychedelic medicine. And he said he’s open to the government issuing vouchers to cover the costs of psychedelic therapy for veterans who receive services outside the VA while Congress considers avenues for access.

Bipartisan members of Congress introduced legislation this session to provide $30 million in annual funding. establish psychedelic-focused “centers of excellence” at the US Department of Veterans Affairs (VA) facility where veterans can receive new treatments containing substances such as psilocybin, MDMA and ibogaine.

A US Senate committee held a hearing last month on a bipartisan bill Promote research into the therapeutic potential of psychedelics by creating a new office at the VA this would help develop innovative treatments for serious mental health conditions and review the scheduling status of drugs such as psilocybin, ibogaine and MDMA.

Former US House Speaker Newt Gingrich (R-GA) said ibogaine represents ‘amazing breakthrough’ in nation’s current ‘patient care system’ this has left people with serious mental health conditions without access to promising alternative treatments.